Lumigan is an ophthalmic medication used to lower intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension. It contains bimatoprost as its active component. The product is supplied in a sterile bottle (3 ml) of preservative-free ophthalmic solution. In Hong Kong, Lumigan is classified as a prescription-only medication and is regulated by the Department of Health’s Pharmacy and Poisons Board. The brand is manufactured by Allergan (an AbbVie company) and marketed under the name Lumigan®.
Lumigan belongs to the class of prostaglandin analogues. Bimatoprost mimics the natural prostaglandin F₂α, binding to prostanoid FP receptors in the eye’s ciliary muscle and trabecular meshwork. This interaction triggers remodeling of extracellular matrix proteins, which enhances uveoscleral outflow of aqueous humour. By increasing drainage, intra-ocular pressure (IOP) is reduced, helping to prevent optic nerve damage associated with glaucoma.
Key pharmacologic points:
Lumigan is approved by the Hong Kong Department of Health for the following indications:
The medication is intended for adult patients, though pediatric use may be considered only under specialist supervision. Clinical studies have demonstrated that nightly administration of bimatoprost reduces IOP by an average of 25-30 % compared with baseline measurements.
Beyond its approved ocular-pressure indications, bimatoprost has been investigated for enhancing eyelash growth. In many jurisdictions, a higher-concentration formulation (Latisse®) is marketed specifically for this purpose. In Hong Kong, using Lumigan for cosmetic eyelash lengthening is off-label and not approved by the regulatory agency.
Disclaimer: Off-label use requires medical supervision and individualized risk assessment.
This article provides educational information about Lumigan and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes, but the lens should be removed before instilling the drop and re-inserted after waiting at least 15 minutes to prevent drug residue from adhering to the lens material.
A single eye-drop is roughly 0.05 ml. A 3 ml bottle therefore contains about 60 doses, providing roughly a two-month supply when dosing one drop nightly per eye.
Systemic absorption of topical bimatoprost is minimal, so systemic side effects are rare. Most reported effects are confined to the ocular surface and peri-ocular tissues.
Bimatoprost is a prostaglandin-F₂α analogue with a slightly higher potency for IOP reduction and a higher incidence of eyelash growth compared with latanoprost, which is a prostaglandin F-type analog.
Pregnancy is a relative contraindication. While animal studies have not shown clear teratogenic effects, the medication should only be used if the potential benefit justifies the possible risk, after consultation with an ophthalmologist.
Mild conjunctival hyperemia often improves with continued use. If redness persists beyond a few weeks or is accompanied by pain or visual changes, contact your eye-care professional promptly.
Older adults may exhibit increased sensitivity to ocular irritation. Regular IOP monitoring and careful assessment of side-effects are recommended.
Yes, prolonged use can cause a permanent increase in brown or black pigment of the iris, especially in patients with mixed-colour irises. This change is generally irreversible.
Lumigan is a prescription medication and may be covered under the Hospital Authority’s drug formulary for eligible patients; reimbursement details vary and should be verified with the treating institution.
